HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis

Pharmacogenetics and Genomics

Volumn 16, Issue 9, 2006, Pages 615-623

  Rizzo, Roberta ^a   Rubini, Michele ^a   Govoni, Marcello ^a   Padovan, Melissa ^a   Melchiorri, Loredana ^a   Stignani, Marina ^a   Carturan, Sabrina ^a   Ferretti, Stefano ^a   Trotta, Francesco ^a   Baricordi, Olavio R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

14 bp polymorphism; HLA G; Methotrexate; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; HLA G ANTIGEN; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESSENGER RNA; METHOTREXATE; PROTEIN;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE INSERTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RNA STABILITY; TREATMENT RESPONSE;

AGED; ANTIGENS, CD14; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC LINKAGE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; INTERLEUKIN-10; LEUKOCYTES; LINKAGE (GENETICS); MALE; METHOTREXATE; MIDDLE AGED; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; STATISTICS; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 33747091959     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000230115.41828.3a     Document Type: Article

References (56)

1. Constantin A, Loubet-Lescoulie P, Lambertt N, Yassine-Diab B, Abbal M, Mazieres B, et al. Anti-inflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1998; 41:48-57.
2. van der Graaff WL, Prins APA, Dijkmans BAC, van Lier RAW. Prognostic value in Th1/Th2 ratio in rheumatoid arthritis. Lancet 1998; 351:1931.
3. Newton JL, Harney SM, Wordsworth BP, Brown MA. A review of the MHC genetics of rheumatoid arthritis. Genes Immun 2004; 5:151-157.
4. Aractingi S, Briand N, Le Danff C, Viguier M, Bachelez H, Michel L, et al. HLA-G and NK receptor are expressed in psoriatic skin: a possible pathway for regulating infiltrating T cells? Am J Pathol 2001; 159:71-77.
5. Khosrotehrani K, Le Danff C, Reynaud-Mendel B, Dubertret L, Carosella ED, Aractingi S. HLA-G expression in atopic dermatitis. J Invest Dermatol 2001; 117:750-752.
6. Fainardi E, Rizzo R, Melchiorri L, Vaghi L, Castellazzi M, Marzola A, et al. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol 2003; 142:149-158.
7. Ober C, Rosinsky B, Grimsley C, van der Ven K, Robertson A, Runge A. Population genetic studies of HLA-G: allele frequencies and linkage disequilibrium with HLA-A1. J Reprod Immunol 1996; 32:111-123.
8. Yamashita T, Fujii T, Watanabe Y, Tokunaga K, Tadokoro K, Juji T, Taketani Y. HLA-G gene polymorphism in a Japanese population. Immunogenetics 1996; 44:186-191.
9. Hviid TV, Meldgaard M, Sorensen S, Morling N. Polymorphism of exon 3 of the HLA-G gene. J Reprod Immunol 1997; 35:31-42.
10. Ishitani A, Kishida M, Sageshima N, Yashiki S, Sonoda S, Hayami M, et al. Re-examination of HLA-G polymorphism in African Americans. Immunogenetics 1999; 49:808-811.
11. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990; 248:220-223.
12. Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997; 186:289-298.
13. Moreau P, Adrian-Cabestre F, Menier C, Guiard V, Gourand L, Dausset J, et al. IL-10 selectively induces HLA-G in human trophoblast and monocytes. Int Immunol 1999; 5:803-811.
14. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum Immunol 2003; 64:1017-1024.
15. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994; 153:5516-5524.
16. Rouas-Freiss N, Marchal RE, Kirszenbaum M, Dausset J, Carosella ED. The alpha1 domain of HLA-G1 and HLA-G2 inhibits cytotoxicity induced by natural killer cells: is HLA-G the public ligand for natural killer cell inhibitory receptors? Proc Natl Acad Sci USA 1997; 94:5249-5254.
17. Fournel S, Aguerre-Girr M, Huc X, Lenfant F, Alam M, Toubert A, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000; 164:6100-6104.
18. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000; 48:17-26.
19. Seliger B, Abken H, Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003; 24:82-87.
20. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003; 13:371-377.
21. Onno M, Pangault C, Le Friec G, Guilloux V, Andre P, Fauchet R. Modulation of HLA-G antigen expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection. J Immunol 2000; 164:6426-6434.
22. Lozano JM, Gonzales R, Kindelan JM, Rouas-Freiss N, Caballo R, Dausset J, et al. Monocytes and T lymphocytes in HIV-1 positive patients express HLA-G molecules. AIDS 2002; 16:347-351.
23. Lila N, Amrein C, Guillemain R, Chevalier P, Latrmouille C, Fabiani JN, Dausset J, et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002; 105:1949-1954.
24. Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E, et al. Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 2003; 11:1033-1038.
25. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001; 10:553-555.
26. Rizzo R, Mapp CE, Melchiorri L, Maestrelli P, Visentin A, Ferretti S, et al. Defective production of soluble HLA-G molecules by peripheral blood monocytes in patients with asthma. J Allergy Clin Immunol 2005; 115:508-513.
27. Hviid TV, Hylenius S, Rorbye C, Nielsen LG. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels. Immunogenetics 2003; 55:63-79.
28. Rousseau P, Le Discorde M, Mouillot G, Marcou C, Carosella ED, Moreau P. The 14 bp deletion-insertion polymorphism in the 3′ UT region of the HLA-G gene influences HLA-G mRNA stability. Hum Immunol 2003; 64:1005-1010.
29. Rebmann V, van der Ven K, Passler M, Pfeiffer K, Krebs D, Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 2001; 57:15-21.
30. Hviid TV, Rizzo R, Christiansen OB, Melchiorri L, Lindhard A, Baricordi OR. HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms. Immunogenetics 2004; 56:135-141.
31. Hviid TV, Hylenius S, Hoegh AM, Kruse C, Christiansen OB. HLA-G polymorphisms in couples with recurrent spontaneous abortions. Tissue Antigens 2002; 60:122-132.
32. Gazit E, Slomov Y, Goldberg I, Brenner S, Loewenthal R. HLA-G is associated with pemphigus vulgaris in Jewish patients. Hum Immunol 2004; 65:39-46.
33. Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, Braun J, Sieper J. Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis 2000; 59:311-314.
34. Pawlik A, Baskiewicz-Masiuk M, Machalinski B, Gawronska-Szklarz B. The effect of methotrexate and glucocorticoids on apoptosis of phythemagglutinin- stimulated mononuclear cells from peripheral blood. Fundament Clin Pharmacol 2005; 19:81-85.
35. Rizzo R, Hviid TV, Stignani M, Balboni A, Grappa MT, Melchiorri L, et al. HLA-HLG genotype is associated with IL-10 levels in activated PBMC. Immunogenetics 2005; 57:172-181.
36. Arnett FC, Edworthy SM, Bloch DA, Mc Shane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998; 31:315-324.
37. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39:34-40.
38. Taniguchi A, Kamatani N. Pharmacogenetics approaches to rheumatoid arthritis. The Pharmacogenom J 2004; 4:350-353.
39. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322-328.
40. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, et al. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33:125-134.
41. Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996; 26:1511-1518.
42. Yang Y, Chu W, Geraghty DE, Hunt JS. Expression of HLA-G in human nuclear phagocytes and selective induction by IFN-gamma. J Immunol 1996; 156:4224-4231.
43. Lefebvre S, Berrih-Aknin S, Adrian F, Moreau P, Poea S, Gourand L, et al. A specific interferon (IFN) stimulated response element of the distal HLA-G promoters binds IFN-regulatory factor 1 and mediates enhancement of this non classical class I gene by IFN-beta. J Biol Chem 2001; 276:6133-6139.
44. Mitsdoerffer M, Schreiner B, Kioeseier BC, Neuhaus O, Dichgans J, Hartung HP, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis. J Neuroimmunol 2005; 159:155-164.
45. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops E. The role of the T cell in autoimmune inflammation. Arthritis Res Ther 2005; 7 (Suppl 2):S4-S14.
46. Kraan MC, Haringman JJ, Weedon H, Barg EC, Smith MD, Ahern MJ, et al. cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004; 63:483-488.
47. Jang E, Kim HR, Cho SH, Paik DJ, Kim JM, Lee SK, et al. Prevention of spontaneous arthritis by inhibiting homeostatic expansion of autoreactive CD4+ T cells in the K/B x N mouse model. Arthritis Rheum 2006; 54:492-498.
48. Fuzzi B, Rizzo R, Criscuoli L, Noci I, Melchiorri L, Scarselli B, et al. HLA-HLG expression in early embryos is a fundamental prerequisite for the obtainment of pregnancy. Eur J Immunol 2002; 32:311-315.
49. Noci I, Fuzzi B, Rizzo R, Melchiorri L, Criscuoli L, Dabizzi S, et al. Embryonic soluble HLA-G as a marker of developmental potential in embryos. Hum Reprod 2005; 20:138-146.
50. Hviid TV, Hylenius S, Lindhard A, Christiansen OB. Association between human leukocyte antigen-G genotype and success of in vitro fertilization and pregnancy outcome. Tissue Antigens 2004; 64:66-69.
51. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl 2):74-78.
52. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 1999; 58:156-163.
53. Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, et al. Very recent onset arthritis: clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 2002; 29:2278-2287.
54. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002; 46:347-356.
55. Mottonen T, Hannonen P, Korpela M, Nissila M, Kautiainen H, Ilonen J, et al. FINnish Rheumatoid Arthritis Combination therapy: delay to institution of therapy and induction of remission using single-drug or combination-disease- modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46:894-898.
56. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002; 46:283-285.